...
首页> 外文期刊>Informatics in Medicine Unlocked >Zika viral proteome analysis reveals an epitope cluster within NS3 helicase as a potential vaccine candidate: An in silico study
【24h】

Zika viral proteome analysis reveals an epitope cluster within NS3 helicase as a potential vaccine candidate: An in silico study

机译:Zika病毒蛋白酶分析显示NS3螺旋酶内的表位簇,作为潜在的疫苗候选者:硅中的在硅中的研究

获取原文
           

摘要

Zika virus (ZIKV), a mosquito-borne flavivirus, is now an emerging global public health concern. Currently, the pathogenicity, genetic diversity and the consequences of ZIKV infection are little known and a protective vaccine against ZIKV is urgently needed. In this study, we have taken an immunoinformatics approach to predict epitope cluster regions in the whole proteome (3423?amino acids) of ZIKV. We used a range of bioinformatics algorithms to determine epitopes of CD8+cytotoxic T-cells (CTL), CD4+helper T-cells (THL) and B cells. We have predicted an epitope cluster of 23 contiguous amino acids (region 1989–2011, WLEARMLLDNIYLQDGLIASLYR) residing on the NS3 helicase protein in the ZIKV proteome. This epitope cluster contains fourteen CD4+(THL) epitopes and six CD8+(CTL) epitopes. Finally, we have validated the epitopes by analysing their binding efficiency (binding energy within ?4.7 to ?6.9?kcal/mol) with specific HLA alleles. The epitope cluster is predicted to provide 93.86% population coverage worldwide. Based on our immunoinformatics analysis, we propose the peptide WLEARMLLDNIYLQDGLIASLYR as a new vaccine candidate against Zika virus for further validation.
机译:Zika病毒(ZIKV)是一种蚊子的黄病毒,现在是一个新兴的全球公共卫生问题。目前,致病性,遗传多样性和ZIKV感染的后果甚至急于,迫切需要对抗ZIKV的保护疫苗。在这项研究中,我们采取了免疫信息学方法来预测ZIKV的整个蛋白质组(3423〜氨基酸)中的表位簇区。我们使用了一系列生物信息学算法以确定CD8 +细胞毒性T细胞(CTL),CD4 +辅助T细胞(THL)和B细胞的表位。我们预测了在ZIKV蛋白质组中驻留在NS3螺旋酶蛋白上的23个连续氨基酸(区域1989-2011,WLEARLDNIIALIASLIASLYR)的表位簇。该表位簇含有14个CD4 +(TH1)表位和六个CD8 +(CTL)表位。最后,我们通过用特异性HLA等位基因分析它们的结合效率(在4.7〜6.9 kcal / mol)中的结合效率(结合能量,将能量置于α.4.7〜6.9〜6.9 kcal / mol)进行了验证。预计表位集群将在全球范围内提供93.86%的人口覆盖范围。基于我们的免疫形成性分析,我们将肽WLEARLDNIYLQDGLIASLIASLIASLIASLIAS作为针对ZIKA病毒的新疫苗候选者进行进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号